| http://www.w3.org/ns/prov#value | - BEVERLY, MA--(Marketwire - February 25, 2013) - Cellceutix Corporation (OTCBB: CTIX) (the Company), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, is pleased to provide shareholders an update on Kevetrin???, the Company's novel drug in development for multi-drug re
|
